Clinical trials: Vasculitis, Central Nervous System
Wegener's Granulomatosis, Vasculitis
Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)
The purpose of this study is to determine the efficacy and safety of a new drug, mycophenolate mofetil, for the treatment of relapses of ANCA-associated vasculitis (Wegener's granulomatosis or microscopic polyangiitis).
- Trial name
- NCT00103792
- Testing
- mycophenolate mofetil, cyclophosphamide
- Where
- Netherlands
- Volunteers
- 84 people
- Sponsor
- University Medical Center Groningen
Temporal Arteritis, Duplex of Temporal Artery
Sensitivity and Specificity of Color Doppler Directed Temporal Artery Biopsy as Compared to Standard Random Biopsy in the Diagnosis of Temporal Arteritis
Introduction Temporal arteritis (TA) is the most common primary vasculitis in the adult population. TA is a systemic multi-organ disease but primarily involves the cranial arteries, especially the temporal artery.
- Conditions
- Temporal Arteritis, Duplex of Temporal Artery, Biopsy of Temporal Artery
- Trial name
- NCT00361192
- Testing
- biopsy of temporal artery
- Where
- Israel
- Sponsor
- Shaare Zedek Medical Center
Vasculitis, Wegener's Granulomatosis
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults.
- Conditions
- Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
- Trial name
- RAVE (NCT00104299)
- Testing
- Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 197 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Polymyalgia Rheumatica, Giant Cell Arteritis
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Background: Polymyalgia rheumatica (PMR) is characterised by pain of the proximal muscles, general symptoms, and raised inflammatory markers. Treatment with prednisolone has several adverse effects.
- Conditions
- Polymyalgia Rheumatica, Giant Cell Arteritis, Adrenal Insufficiency
- Trial name
- NCT04519580
- Testing
- PET/CT
- Where
- 3 sites in Denmark
- Volunteers
- 98 people
- Sponsor
- Kresten Krarup Keller
Giant Cell Arteritis
Assessment of Giant Cell Arteritis Medical Practices in France
The purpose of this study is to describe medical practices in patients with GCA in terms of patient journey, diagnostic methods and specific GCA treatments since diagnosis.
- Trial name
- ARTEMIS (NCT03658889)
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Chugai Pharma France
Giant Cell Arteritis
Investigation of the Influence of the Human Microbiome on Giant Cell Arteritis
The longitudinal observational study aims to assess the impact of the microbiome especially the gut-microbiome in the emergence and course of giant cell arteritis (abbr. GCA) patients.
- Trial name
- GCA-Biom (NCT06279065)
- Testing
- Analysis of blood and microbiome samples (stool, oral lavage)
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Giant Cell Arteritis
Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis
OBJECTIVES: I. Compare the long term outcomes in patients with giant cell arteritis after glucocorticoid treatment with or without methotrexate. II.
- Trial name
- NCT00004686
- Testing
- methotrexate, prednisone
- Volunteers
- 300 people
- Sponsor
- The Cleveland Clinic
Wegener's Granulomatosis, Churg-Strauss Syndrome
Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
The Systemic Necrotizing Vasculitides (SNV) encompass a group of rare diseases which include Wegener's Granulomatosis (WG), Churg-Strauss Syndrome (CSS), Microscopic polyangiitis (MPA)and Polyarteritis nodosa (PAN).
- Conditions
- Wegener's Granulomatosis, Churg-Strauss Syndrome, Microscopic Polyangiitis, Polyarteritis Nodosa
- Trial name
- NCT00751517
- Testing
- Methotrexate, Cyclophosphamide
- Where
- Italy
- Sponsor
- University of Parma
Systemic Lupus Erythematosus
Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus
The purpose of this study is to determine whether Libman-Sacks endocarditis (inflammation of the heart valves) is the cause of neuropsychiatric manifestations (stroke, transient ischemic attacks, cognitive dysfunction, seizures…
- Trial name
- NCT00858884
- Testing
- Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of New Mexico
Vasculitis, Systemic Vasculitis
Journey of Patients With Vasculitis From First Symptom to Diagnosis
This study seeks to understand the journey that patients eventually are diagnosed with vasculitis experience in the period prior to their formal diagnosis by a healthcare provider.
- Conditions
- Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis
- Trial name
- NCT03410290
- Testing
- Online Questionnaire
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- University of Pennsylvania
Giant Cell Arteritis (GCA)
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
This is a multi-center, randomized, open label study that will assess the efficacy and safety of ACTEMRA(R) or one of its FDA-approved biosimilars Tocilizumab (TCZ) maintenance versus withdrawal in Giant cell arteritis (GCA)…
- Trial name
- NCT07108387
- Testing
- Tocilizumab, Discontinue Tocilizumab
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Giant Cell Arteritis (GCA)
Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone
The GISCO study plans to determine whether 8-week therapy is just as effective as 26-week cortisone therapy for treating giant cell arteritis with tocilizumab, while using less cortisone.
- Trial name
- GISCO (NCT06833411)
- Testing
- Prednisone
- Where
- Switzerland
- Volunteers
- 178 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Inflammatory Rheumatism, Polymyalgia Rheumatica
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid therapy.
- Conditions
- Inflammatory Rheumatism, Polymyalgia Rheumatica, Giant Cell Arteritis, Idiopathic Inflammatory Myopathies
- Trial name
- PRODIGIOUS (NCT04664465)
- Where
- 12 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest
Giant Cell Arteritis (GCA)
Kinetics of C-Reactive Protein in Giant Cell Arteritis Following Glucocorticoid Initiation: A Pilot Study (GIDEON)
We propose to analyze the kinetics of the main marker of inflammation in GCA in order to understand its links with initial clinical manifestations and the possible appearance of complications and/or relapses.
- Trial name
- GIDEON (NCT07720804)
- Testing
- Blood tests to measure CRP
- Volunteers
- 40 people
- Sponsor
- University Hospital, Limoges
Giant Cell Arteritis
TARGET GCAT Registry
A longitudinal post-marketing surveillance registry nested within the UK GCA Consortium that assesses the effectiveness and safety of tocilizumab in controlling refractory or relapsing forms of GCA in patients who require…
- Trial name
- NCT04049071
- Where
- 34 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Leeds
Polyarteritis Nodosa, Microscopic Polyangiitis
CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors
To assess the efficacy of systemic corticosteroids alone as first-line treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors as defined by the five-factor score (FFS=0), and to compare the…
- Trial name
- NCT00400075
- Testing
- azathioprine, cyclophosphamide
- Where
- Switzerland
- Volunteers
- 124 people
- Sponsor
- Hospices Civils de Lyon
Wegener Granulomatosis, Microscopic Polyangiitis
PRO Development for ANCA Associated Vasculitis
A qualitative study using interviews with patients who have antineutrophil cytoplasm antibody (ANCA) associated vasculitis, to develop a patient reported outcome (PRO)measure
- Conditions
- Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome
- Trial name
- NCT01729624
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Oxford
Giant Cell Arteritis
Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)
Giant cell arteritis (GCA) (or Horton's disease) is a segmental and focal inflammatory arteritis affecting large and medium-sized arteries.
- Trial name
- SPARTA (NCT05854927)
- Testing
- 3D T1 MRI sequences injected with fat saturation and black blood
- Where
- France
- Volunteers
- 133 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Giant Cell Arteritis (GCA), Doppler Ultrasound
Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients
Giant cell arteritis (GCA) is a rare disease characterized by vasculitis of the large arterial trunks targeting the thoracic aorta and its dividing branches, affecting adults over the age of 50.
- Trial name
- Halo-A (NCT07060274)
- Testing
- Doppler Ultrasound
- Where
- 6 sites in France
- Volunteers
- 64 people
- Sponsor
- Centre Hospitalier le Mans
Wegener's Granulomatosis or Microscopic Polyangiitis
A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
This is a perspective, Phase IV, multi-center, single arm, open-label, interventional study in adult participants with Wegener's granulomatosis (granulomatosis with polyangiitis [GPA]) or microscopic polyangiitis.
- Trial name
- NCT02115997
- Testing
- Methylprednisolone, Prednisone, Rituximab
- Where
- 10 sites in India
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche